Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"LISCure Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"LISCure Biosciences Successfully Raises $21 million in Series B Funding","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"LISCure Biosciences"},{"company":"LISCure Biosciences","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LISCure Biosciences How License Agreement ,Stock Purchase Agreement Mayo Clinic","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"LISCure Biosciences"},{"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olyx to Present Liver Disease Treatment and Base Technology at OTS Conference in 2021","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"OliX Pharmaceutical"},{"company":"Tiumbio","sponsor":"Oncodesign","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Tiumbio"}]

Tiumbio

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates

Details:

Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.

Lead Product(s): Nanocyclix Drug Candidates

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Oncodesign

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration October 21, 2021

ASK
US

Upload
your Pipeline Activity

OliX Pharmaceutical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Olyx to Present Liver Disease Treatment and Base Technology at OTS Conference in 2021

Details:

OLX702A, an investigational RNAi therapeutic for the treatment of nonalcoholic steatohepatitis (NASH). OliX will also present its pipeline OLX101A for hypertrophic scars, OLX104C for hair loss, OLX301A/D for age-related macular degeneration and subretinal fibrosis.

Lead Product(s): OLX702A

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: OLX702A

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 27, 2021

ASK
US

Upload
your Pipeline Activity

LISCure Biosciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

LISCure Biosciences How License Agreement ,Stock Purchase Agreement Mayo Clinic

Details:

LISCure Biosciences will receive Mayo Clinic's know-how to establish a new drug, LB-P8, development of NASH program. As part of the agreement, Mayo Clinic will become a shareholder in LISCure, the first Korean biotech company receiving equity investment from Mayo Clinic.

Lead Product(s): LB-P8

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: LB-P8

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Mayo Clinic

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement July 27, 2021

ASK
US

Upload
your Pipeline Activity

LISCure Biosciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

LISCure Biosciences Successfully Raises $21 million in Series B Funding

Details:

LISCure is developing the world's first microbiome-based NASH(non-alcoholic steatohepatitis) treatment, LB-P8, as well as the rheumatoid arthritis treatment, LB-P6, for global clinical trials.

Lead Product(s): LB-P8

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: LB-P8

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $21.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing February 26, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY